文献速递心脏核医学放射性药物与辐射防护

转甲状腺素蛋白心脏淀粉样变患者肺不张组织对99mTc-PYP的滞留

99mTc-Pyrophosphate Retention in Atelectatic Pulmonary Tissues of a Patient With Transthyretin Cardiac Amyloidosis.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本文报告1例61岁男性因疑似心脏淀粉样变接受99mTc-焦磷酸盐(99mTc-PYP)显像,心脏放射性摄取高于肋骨,提示转甲状腺素蛋白心脏淀粉样变,基因检测发现转甲状腺素蛋白基因错义突变而确诊。SPECT/CT定位CT显示双肺局灶性摄取分别对应肺不张区域,提示肺不张的示踪剂滞留会影响H/CL(心脏与对侧肺)比值计算,可能干扰基于定量H/CL比值的心脏淀粉样变诊断。

要点

  • 肺不张组织可滞留99mTc-PYP,形成肺内局灶性摄取
  • 肺内滞留会影响H/CL比值计算,可能干扰心脏淀粉样变定量诊断
  • 判读H/CL比值时应结合SPECT/CT定位CT排除肺不张影响

核心结论

  • 肺不张肺组织可出现99mTc-PYP滞留,影响H/CL比值计算,并可能妨碍基于定量H/CL比值的心脏淀粉样变诊断。

研究设计与样本

  • 单例病例报告:1例61岁男性因疑似心脏淀粉样变住院,行99mTc-PYP闪烁显像及SPECT/CT,并结合基因检测。

主要发现

  • 99mTc-PYP显像显示心脏放射性摄取较肋骨强烈,提示转甲状腺素蛋白心脏淀粉样变。
  • 基因检测显示转甲状腺素蛋白基因错义突变,确诊该病。
  • SPECT/CT定位CT见双肺局灶性放射性摄取,分别对应肺不张区域。

关键数值与推荐

  • 心脏摄取高于肋骨作为提示转甲状腺素蛋白心脏淀粉样变的显像依据;基因检测错义突变用于确诊。
  • 肺不张处示踪剂滞留会影响H/CL(心脏与对侧肺)比值计算。

临床怎么用

  • 行99mTc-PYP显像判读H/CL比值时,应结合SPECT/CT定位CT识别肺不张所致局灶性摄取,避免误判。

局限性

  • 为单例病例报告,不能外推发生率或诊断阈值;未报告定量H/CL数值及随访结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 61-year-old man was hospitalized for suspected cardiac amyloidosis. 99mTc-Pyrophosphate scintigraphy showed intense radiotracer uptake in the heart compared with the ribs, suggestive of transthyretin cardiac amyloidosis. Subsequent genetic test showed missense mutations in the transthyretin gene, which confirmed the diagnosis. Incidentally, a regional radiotracer uptake was seen in the bilateral lungs, respectively, corresponding to areas of atelectasis on the localizing CT of the SPECT/CT. Attention should be paid to radiotracer retention in lung atelectasis as it influences the H/CL (heart-to-contralateral lung) ratio calculation and may hinder the diagnosis of cardiac amyloidosis based on the quantitative H/CL ratio.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pan Y, Wang Y, Zhou Y, et al. 99mTc-Pyrophosphate Retention in Atelectatic Pulmonary Tissues of a Patient With Transthyretin Cardiac Amyloidosis. Clin Nucl Med. 2021. PMID: 34269728. doi:10.1097/RLU.0000000000003816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。